Share >  
Share
Share on Tumblr

Vvs Murthy

News »

   latest by relevance
Creapharm buy funded via internal accruals: Dishman Pharma
Jan 19, 2012 at 14:44 | Source: CNBC-TV18
Dishman Pharmaceuticals and Chemicals' subsidiary Carbogen Amcis AG has acquired Creapharm Parenterals. In an interview to CNBC-TV18, VVS Murthy, chief financial officer of Dishman Pharma says, it is a small R&D formulation development company. The acquisition, he says, is funded trough internal accruals.
Dishman Pharma may end FY12 with marginal net profit
Sep 21, 2011 at 15:13 | Source: PTI
In an interview to CNBC-TV18, Dishman Pharma's chief financial officer VVS Murthy said that the change in rupee would not impact the companys revenues. Murthy projects a flat topline growth for FY12.
Dishman Pharma expects 15% consolidated growth, says CFO
Jul 21, 2011 at 15:55 | Source: CNBC-TV18
In an exclusive interview with CNBC-TV18, VVS Murthy, CFO of Dishman Pharma says that the company has announced a consolidated guidance of 21.5-22% EBITDA margins and is expecting 15% growth on a consolidated level for FY12.
Dishman Pharma eyes 15% topline, bottomline growth in FY12
Jun 13, 2011 at 15:30 | Source: CNBC-TV18
In an interview with CNBC-TV18, VVS Murthy, CFO, Dishman Pharma said the company is expecting 15% top-line and bottom-line growth in FY12.
Dishman Pharma eyes 15% growth in FY12
Feb 22, 2011 at 17:09 | Source: CNBC-TV18
VVS Murthy, CFO of Dishman Pharma, in an interview with CNBC-TV18's Latha Venkatesh and Gautam Broker, spoke about the recent report by one of the brokerages Indiabulls Securities, which downgraded the company's stocks and the road ahead.
Q4 to be better compared to Q3: Dishman Pharma
Feb 14, 2011 at 18:59 | Source: CNBC-TV18
Dishman Pharma has reported a consolidated net profit of Rs 1.7 crore for the quarter ended December 2010 as against Rs 33 crore in same quarter, the previous year. The company's consolidated net sales increased to Rs 230 crore from Rs 220 crore (YoY).

Videos »
Creapharm buy funded via internal accruals: Dishman Pharma
Dishman Pharma expects 15% consolidated growth, says CFO
Dishman Pharma eyes 15% topline, bottomline growth in FY12
Dishman Pharma eyes 15% growth in FY12
Dishman Pharma lowers margins by 1% for yr due to slow H1
more »

Photos »

  /  
Interact & exchange stock tips & market info »

saroyogi

Silver Member

0 Follower

Just Posted  

VVS Murthy\\`s addition is a gain to Granules India and...

2.17 PM May 1st

Web Messenger

Platinum Member

107829 Followers

Dishman Pharma  

Source:Business Standard - Granules India Limited has appointed VVS...

4.50 PM Apr 30th

Web Messenger

Platinum Member

107829 Followers

Granules India  

Source:Business Standard - Granules India Limited has appointed VVS...

4.50 PM Apr 30th

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window